Accordingly, the European LeukemiaNET (ELN) guidelines recommend FLT3 testing at the time of initial AML diagnosis to guide treatment decisions and assess patient eligibility for allogeneic hematopoietic stem cell transplantation (allo-HSCT). The gene discussed is FLT3; the disease is acute myeloid leukemia.